William A Denny
William A Denny
Distinguished Professor, The University of Auckland
Verified email at
Cited by
Cited by
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
DW Fry, AJ Bridges, WA Denny, A Doherty, KD Greis, JL Hicks, KE Hook, ...
Proceedings of the National Academy of Sciences 95 (20), 12022-12027, 1998
Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality
DA Chan, PD Sutphin, P Nguyen, S Turcotte, EW Lai, A Banh, ...
Science translational medicine 3 (94), 94ra70-94ra70, 2011
Tyrosine kinase inhibitors. 8. An unusually steep structure− activity relationship for analogues of 4-(3-bromoanilino)-6, 7-dimethoxyquinazoline (PD 153035), a potent inhibitor …
AJ Bridges, H Zhou, DR Cody, GW Rewcastle, A McMichael, ...
Journal of medicinal chemistry 39 (1), 267-276, 1996
Prodrug strategies in cancer therapy
WA Denny
European journal of medicinal chemistry 36 (7-8), 577-595, 2001
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of minimal DNA-intercalating agents which may not act via …
WA Denny, GW Rewcastle, BC Baguley
Journal of medicinal chemistry 33 (2), 814-819, 1990
Interactions of antitumor drugs with natural DNA: proton NMR study of binding mode and kinetics
J Feigon, WA Denny, W Leupin, DR Kearns
Journal of medicinal chemistry 27 (4), 450-465, 1984
Acridine derivatives as chemotherapeutic agents
WA Denny
Current Medicinal Chemistry 9 (18), 1655-1665, 2002
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino) quinazoline-and 4-(phenylamino) pyrido [3, 2-d] pyrimidine-6 …
JB Smaill, GW Rewcastle, JA Loo, KD Greis, OH Chan, EL Reyner, ...
Journal of medicinal chemistry 43 (7), 1380-1397, 2000
DNA-intercalating ligands as anti-cancer drugs: prospects for future design.
WA Denny
Anti-cancer drug design 4 (4), 241-263, 1989
Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl) amino]-and 4-(phenylamino) quinazolines as potent adenosine 5'-triphosphate …
GW Rewcastle, WA Denny, AJ Bridges, H Zhou, DR Cody, A McMichael, ...
Journal of medicinal chemistry 38 (18), 3482-3487, 1995
Two-dimensional proton nuclear magnetic resonance investigation of the synthetic deoxyribonucleic acid decamer d (ATATCGATAT)
J Feigon, W Leupin, WA Denny, DR Kearns
Biochemistry 22 (25), 5943-5951, 1983
Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring
BC Baguley, WA Denny, GJ Atwell, BF Cain
Journal of medicinal chemistry 24 (2), 170-177, 1981
Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
AJ Bridges, WA Denny, D Fry, A Kraker, RF Meyer, GW Rewcastle, ...
US Patent 5,654,307, 1997
A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy
S Turcotte, DA Chan, PD Sutphin, MP Hay, WA Denny, AJ Giaccia
Cancer cell 14 (1), 90-102, 2008
A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation
J Datta, K Ghoshal, WA Denny, SA Gamage, DG Brooke, P Phiasivongsa, ...
Cancer research 69 (10), 4277-4285, 2009
Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino) ethyl] acridine-4-carboxamide
GJ Atwell, GW Rewcastle, BC Baguley, WA Denny
Journal of medicinal chemistry 30 (4), 664-669, 1987
Genotoxicity of non-covalent interactions: DNA intercalators
LR Ferguson, WA Denny
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 623 (1 …, 2007
Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling
C Chaussade, GW Rewcastle, JD Kendall, WA Denny, K Cho, ...
Biochemical Journal 404 (3), 449-458, 2007
Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids
GW Rewcastle, GJ Atwell, L Zhuang, BC Baguley, WA Denny
Journal of medicinal chemistry 34 (1), 217-222, 1991
Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104
AV Patterson, DM Ferry, SJ Edmunds, Y Gu, RS Singleton, K Patel, ...
Clinical Cancer Research 13 (13), 3922-3932, 2007
The system can't perform the operation now. Try again later.
Articles 1–20